The American Academy of Dermatology (AAD) and the International League of Dermatological Societies (ILDS) have added a monkeypox dermatology registry to the existing COVID-19 registry.
The ADD/ILDS Dermatology COVID-19, Monkeypox and Emerging Infections Registry was founded after monkeypox symptoms were added to the COVID-19 registry, following the classification of the disease as a public health emergency in the US. Monkeypox also exists in the UK, with 3,500+ confirmed cases as of the beginning of October, 2022.
The ADD/ILDS Registry is designed to help practitioners identify the dermatological symptoms of monkeypox, in turn aiding them in understanding treatment options.
Esther Freeman, dermatology professor at Harvard Medical School, said, “Monkeypox is particularly important for dermatologists to be aware of because the classic clinical course of the disease nearly universally encompasses a skin rash. In the current 2022 outbreak, we are seeing more than half of patients present with cutaneous manifestations either prior to or during the onset of the systemic symptoms. Dermatologists are uniquely positioned to be able to recognise these findings and provide testing, treatment and guidance for patients.”
Practitioners can access the registry for more details here.
